Praventin to be Launched in Natural Acne Treatment

Recently nominated for the best ingredient innovation award at the 2006 Health Ingredients Europe Show, F2F’s Praventin provides a much sought after natural yet highly effective solution to this socially debilitating condition.

22/11/06 The UK market is set to see the launch of Face To Face (F2F), a highly anticipated and exclusive new and 100% Natural Acne treatment. The launch is supported by an integrated marketing and PR campaign which focuses on the unique and natural benefits of F2F and the active ingredient Praventin from DMV International. Following huge success in 9 other countries the UK launch will provide hope to Britain’s many acne suffers.

Praventin enhances the body’s natural defences to fight the bad bacteria that cause acne, supporting a healthy complexion from within. Recently nominated for the best ingredient innovation award at the 2006 Health Ingredients Europe Show, F2F’s Praventin provides a much sought after natural yet highly effective solution to this socially debilitating condition.

Praventin from DMV International is claimed to be the first scientifically supported natural product that delivers the smooth, blemish-free complexion that consumers desire. The natural ingredient is rich in milk protein fractions including lactoferrin and is easily formulated into functional food applications, creating a new category of innovative healthy products to help consumers improve the appearance of their skin. “Praventin is one of the first bioactive ingredients to reduce the appearance of blemishes and redness associated with a poor complexion. This gives consumers an advantage of seeking natural actives in their pursuit of a healthy clearer looking complexion”, says Rick de Waard at DMV. De Waard pointed out that in recent years the supplementation of actives in functional foods and supplements has sparked a renewed interest in establishing a new category for the skin enhancing properties of food actives. Based on secondary research, the market trend of consumers seeking beauty benefits through food and supplementation has seen a 17% CAGR between 2000 and 2005, he noted, with predictions that this market will grow by 9% by 2010 or $2.2 million.

A recent study clearly demonstrated that oral intake of F2F is statistically and clinically significant in reducing the blemishing associated with acne affecting both the face and body, showing a 71% decrease in blemishes after one month and 95% after two months.

Consumer studies soon to be published in a peer reviewed journal, have taken place in both the USA and India. These three studies have shown that Praventin can be used to improve blemishes associated with a bad complexion. The effects of Praventin were observed in people with different skin types, different local diets and in different seasons, demonstrating Praventin’s efficacy, independent of influential factors such as gender, race, diet and seasons.

After a hugely successful trial in the Netherlands, a UK trial is also underway and fuelling much PR activity with an array of both male and female case studies and results expected in December 2006.

Praventin has no adverse side effects. Other widely available drugs to treat acne and poor skin have been associated with serious side effects such as birth defects and depression. The World Health Organisation has reported a link to the drug Roaccutane and reports of 720 cases of psychiatric problems, including 84 suicides and suicide attempts. Dianette, another licensed hormone treatment for severe acne has also been reviewed by The Medicines and Healthcare Products Regulatory Authority (MHRA) due to claims that more than 100 women who say they became seriously depressed after taking Dianette. The manufacturer also warms that one of the possibly side effects of taking the drug is ‘mild depression’

F2F is promoted as providing the safe and natural alternative for healthy skin that UK consumers have been waiting for. F2F is a new and unique product, with proven success and with benefits that clearly outweigh any other product on the market.

To contact our editorial team please email us at editorial@cnsmedia.com